1
=> ÀúºÐÀÚ ¼ö¿ë¼º Å°Åä»ê
=> À¯±â °Ô¸£¸¶´½
=> ½ÉÇ÷°ü ´ç´¢ °ü·Ã(Áö··ÀÌ)
=> ¸¶ÀÌ´ÙÄÉ
=> ¾Æº£¸¶¸£(Avemar)
=> ÇÁ·ÎÆú¸®½º
=> D-12
=> ŸÈ÷º¸(ÀÌÆó)
=> Willard Water Clear
=> ºñŸ¹Î B 17
=> ÄÝ·ÎÀÌµå ½Ç¹ö(Àº¿ë¾×)
=> Â÷°¡¹ö¼¸ ÃßÃâ¹°
=> ²É¼ÛÀÌ ¹ö¼¸(Á¤Å¸ÀÔ)
=> ÇÙ»ê
=> »ó¾î¿¬°ñ
=> Á¦ºñÁý °Ç°­½ÄÇ°
=> ÀϺ» È÷Æ®»óÇ° ¸ðÀ½(ÇÖÆÑ¿Ü)
=> À¯»ê±Õ
=> µ¶ÀÏ ´ÚÅͺ¼Ã÷ ¸é¿ª Á¦Ç°
=> ¾î¸°ÀÌ Ã»¼Ò³â Å°¼ºÀå Á¦Ç°
=> È¿¼Ò
   ÇöÀçÀ§Ä¡ : HOME > => ¾Æº£¸¶¸£(Avemar) 

¾Æº£¸¶¸£ Ÿºí·¿ 150Á¤ * 4º´
  ÆǸŰ¡°Ý     ¿ø  
  ¿ø»êÁö Çë°¡¸®
  Àç°í ÆǸÅÁß
  ±¸¸Å¼ö·® EA  
  
 

 


¾Æº£¸¶¸£ Á¤Å¸ÀÔ 150Á¤/º´ * 4º´

 

 

±âÁ¸ ÆÄ¿ì´õ ŸÀÔº¸´Ù µå½Ã±â ÆíÇÏ°Ô Á¤Å¸ÀÔÀ¸·Î °³¹ß µÈ »óÇ°ÀÔ´Ï´Ù.

¾Æº£¸¶¸£ Ÿºí¸´ 10Á¤Àº ÆÄ¿ì´õ 1Æ÷¿Í °°Àº ¾çÀÔ´Ï´Ù...

(150Á¤ 2º´Àº ÆÄ¿ì´õ Á¦Ç° 1¹Ú½º¿Í µ¿ÀÏ)

 

 

º¹¿ë¹ý

 

90Å°·Î ÀÌÇÏÀÇ ºÐÀº ÇÏ·ç 5Á¤¾¿ 2ȸ º¹¿ëÇÕ´Ï´Ù..

90Å°·Î ÀÌ»óÀÎ ºÐÀº 7Á¤¾¿ 2ȸ º¹¿ëÇÕ´Ï´Ù...

 

* º¹¿ë·®Àº °¡°¨Çϼŵµ ÁÁ½À´Ï´Ù...

* ¼·¾¾ 22µµ ÀÌÇÏ¿¡¼­ º¸°üÇÏ½Ã¸é µË´Ï´Ù..

 

 

 

¾Æº£¸¶¸£ Ÿºí¸´ »óÇ°Àº À¯·´¿¬ÇÕ(EU) ¹× À¯·´Áö¿ª°³¹ß ±â±ÝÀÇ Áö¿ø¾Æ·¡

°³¹ß µÇ¾ú½À´Ï´Ù..

 

Çؿܹè¼Û »óÇ°À̹ǷΠ¹è¼Û±â°£ÀÌ 10ÀÏ ÀÌ»ó ¼Ò¿äµË´Ï´Ù..

 

¿©À¯¸¦ °®°í ½ÅûÇØ ÁÖ¼¼¿ä.

 

Avemar Tablet

The Avemar film-coated tablet is a dietary food for special medical uses for cancer patients, containing Avemar pulvis, a fermented wheat germ extract.

Each bottle of Avemar tablet contains 150 tablets. Avemar tablet form does not contain any fructose or additional flavoring.

 

User Information

 

Recommended Dosage:


For adults with body weight less than 50 kg: four tablets twice a day.

For adults with body weight between 50-90 kg: five tablets twice a day.
For adults with body weight above 90 kg: 7 tablets twice a day.


It is recommended to take half of the daily dose in the morning and the other half in the evening. 10 tablets of Avemar are equal to one sachet (17g) of Avemar granulate.

 

Based on this recommended dosage 150 tablets are sufficient for 11-18 days depending on bodyweight. Avemar tablet is easier to store, transport and dose, than the granulate form.

 

Storage Requirements: The Avemar tablet must be stored in conditions below 22 ¢ªC degrees. A refrigerated environment is a suggested option.

 

Before consuming Avemar, please read the detailed user information in the box!

 

The development of the new Avemar film-coated tablets was funded by the European Union and the European Regional Development fund.

 

 


GENERAL STUDIES

These general studies are provided to show the positive impacts Avemar has as an alternative or Complementary Cancer Treatment. General studies and overall scientific research have proven that Avemar can help or replace traditional cancer treatments such as Melanoma Cancer Treatment, Breast Cancer Treatment, leukaemia cancer treatment and Colon Cancer Treatment.
 
1. The role of antioxidant supplement in immune system, neoplastic, and neurodegenerative disorders: a point of view for an assessment of the risk/benefit profile.

'[Avemar] has shown immunomodulatory and antitumor activity in a variety of preclinical studies and several human trials.'
 
Nutrition Journal Volume 7, Issue 29: 29-35. 2008.
Brambilla D., Mancuso, C., Scuderi, M.R., Bosco, P., Cantarella, G., Lempereur, L.,
Di Benedetto, G., Pezzino, S., Bernardini, R.
Scientific Paper No 56 General-Studies1-pdf56.pdf

 
2. Experimental and clinical results with Avemar (a dried extract from fermented wheat germ) in animal cancer models and in cancer patients.

Nõgyógyászati Onkológia 7: 180-185. 2002.
Nichelatti M, Hidvégi M:
Scientific Paper - No 27 General-Studies2-pdf27.pdf

 
3. Synergistic Effect of Avemar on Proinflammatory Cytokine Production and Ras-Mediated Cell Activation.

ABSTRACT: Macrophages activated by lipopolysaccharide and/or phorbol esters exhibited high sensitivity to Avemar, a fermented wheat germ extract. Avemar synergized with lipopolysaccharide and PMA in the induction of the transcription of cytokine genes and release of inflammatory cytokines. At higher concentrations the preparation had a significant negative effect on the proliferation and survival of activated myeloid cell types. Avemar treatment induced the synthesis of ICAM-1 and synergized with the ICAM-inducing effect of TNF, but had no effect on VCAM-1 expression on microvascular endothelial cells. The effect of Avemar on signalling pathways, which are involved in cell activation was studied on HeLa cells as a model system. Avemar treatment increased the activity of stress kinases in a concentration-dependent way, resulting in the activation of AP-1 transcription factor. NF-kappa B-sensitive reporters were also activated by Avemar; in contrast, no effect of the preparation was observed on PKA-sensitive signalling pathways.
 
András Telekes, Endre Kiss-Tóth, Tünde Nagy:
Ann. N.Y. Acad. Sci. 1051: 515-528. 2005.
Scientific Paper - No 43 General-Studies3-pdf43.pdf

 
4. Immunologic and Biochemical Effects of the Fermented Wheat Germ Extract Avemar.

Biology and Medicine 230/2: 144-149. 2005.
Illmer C, Madlener S, Horvath Z, Saiko P, A. Losert, Herbacek I, Grusch M, Krupitza G, Fritzer-Szekeres M, Szekeres T Medical University of Vienna, Austria.
Scientific Paper - No 40 General-Studies4-pdf40.pdf

 
5. Fermented wheat germ extract reduces chemotherapy-induced febrile neutropenia in pediatric cancer patients.
 
'The ability of this medical nutriment to accelerate regeneration of the hematopoietic system, reconstruct healthy immune response, and increase hematopoietic interleukin gene expression may explain it's possible febrile neutropenia-preventing effect in children receiving cytotoxic therapies.'
 
J. Pediatr Hematol Oncol 10: 631-635. 2004.
Garami M, Schuler D, Babosa M, Borgulya G, Hauser P, Müller J, Paksy A, Szabó E, Hidvégi M, Fekete Gy:
Scientific Paper - No 35 General-Studies5-pdf35.pdf

 
6. Metabolic control analysis in drug discovery and disease.
 
'Other examples of natural and synthetic tumour-growth inhibitors are genestein and the wheat germ extract AVEMAR, both of which strongly inhibit the use of glucose for nucleic acid synthesis as a central mechanism for their anti-proliferative action. As non-oxidative ribose synthesis is almost unique to most types of tumours, enzyme inhibitors with high control coefficients in both glucose use and non-oxidative anabolic glucose use for de nova nucleic acid synthesis are likely to be of great value in future cancer treatment protocols.'
 
Nature Biotechnol 20: 243-249. 2002.
Cascante M, Boros L. G, Comin-Anduix B, Atauri P, Centelles J. J, Lee W-N. P:
Scientific Paper - No 29 General-Studies6-pdf29.pdf

 
7. The effect of Avemar and Avemar + vitamin C on tumor growth and metastasis in experimental animals.
 
'[Avemar] lived up to our expectations, has indeed shown powerful biological activity, and proved able to stimulate the immune functions in hosts with severely impaired immune system. It has shown a powerful metastasis inhibiting effect in several tumour models without eliciting toxic side effects. It is our hope that this preparation will find a place in biotherapeutical treatment of human cancer.'
 
Anticancer Res 18: 2353-2358. 1998.
Hidvégi M, RásóE, Tömösközi-Farkas R, Paku S, Lapis K, Szende B:
Scientific Paper - No 1 General-Studies7-pdf1.pdf

 
8. Effect of MSC [Avemar] on the immune response of mice.
 
'The immune restoring effect, as well as the blastic transformation enhancing potential of MSC [Avemar] may be exploited in various cases of decreased immune response.'
 
Immunopharmacology 41: 183-186. 1999.
Hidvégi M, RásóE, Tömösközi-Farkas R, Lapis K, Szende B:
Scientific Paper - No 4 General-Studies8-pdf4.pdf

 
9. MSC, [Avemar] a new benzoquinone-containing natural product with antimetastatic effect.
 
'Our in vitro and in vivo experiments with Avemar refer to a very significant anti-metastatic effect of this product observed in several animal experimental models. Most likely this effect correlates with the immune stimulatory effect manifested in both in vivo and in vitro tests, although the anti-proliferative, apoptotic, adhesion-related, as well as free radical-forming effects may all contribute to the fewer number of metastases, too.'
 
Cancer Biother Radiopharm 14: 277-289. 1999.
Hidvégi M, RásóE, Tömösközi-Farkas R, Lapis K, Szende B:
Scientific Paper - No 5 General-Studies9-pdf5.pdf

 
10. Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines.
 
Int J Oncol 20: 563-570. 2002.
Fajka-Boja R, Hidvégi M, Shoenfeld Y, Ion G, Demydenko D, Tömösközi-Farkas R, Vizler Cs, Telekes A, Resetár Á, Monostori É:
Scientific Paper - No 26 General-Studies10-pdf26.pdf
 
 
REVIEW ARTICLES
 
Each article listed is designed to give you a technical and knowledgeable insight into Avemar as an alternative and Complementary Cancer Treatment. From powerful cancer research, Avemar has been proven to help with, and act as an alternative to Breast Cancer Treatment, Colon Cancer Treatment, leukaemia cancer treatment, Melanoma Cancer Treatment and also as an Autoimmune Treatment.

1. Efficacy of a medical nutriment in the treatment of cancer.

"This review article is designed to meet the educational needs of physicians and other healthcare professionals who diagnose, treat and manage patients who have or are at risk of cancer. Upon completion of this article, participants should be able to:

1. Define Avemar and discuss its safety profile.
2. Describe the mechanisms by which Avemar exerts its anti-cancer activity.

3. Review the efficacy of Avemar in cancer prevention and therapy, both in animal models and human clinical trials.'
Alternative Therapies Health Med. Mar-Apr;13(2): 56-63. 2007 Johanning GL, Wang-Johanning F
Scientific Paper - No. 49 Review-Article1-pdf49.pdf

2. Fermented Wheat Germ Extract (Avemar) in the Treatment of Cancer and Autoimmune Diseases.

This article displays how Avemar assists in cancer treatment and also acts as an Autoimmune Treatment.

'ABSTRACT: Avemar, the product of industrial fermentation of wheat germ, possesses unique cancer-fighting characteristics. Taken orally, Avemar can inhibit metastatic tumour dissemination and proliferation during and after chemotherapy, surgery, or radiation.
 
Benefits of Avemar treatment have been shown in various human cancers, in cultures of in vitro grown cancer cells, in the prevention of chemical carcinogenesis, and also in some autoimmune conditions.
 
This document reviews the clinical and experimental results obtained with this extract so far. Special references are made for its safety, including its co-administration with anticancer drugs, as well as for its immuno-modulatory activity, its molecular targets, and its use in cancer clinical trials.'

Ann. N.Y. Acad. Sci. 1051: 529-542. 2005. Laszlo G. Boros, Michele Nichelatti, Yehuda Shoenfeld:
Scientific Paper - No 42 Review-Article2-pdf42.pdf

3. Is It Really From Heaven? The cancer miracle that leaves healthy cells healthy
Avemar is the Alternative Cancer Treatment that many have been searching for. Research has found that Avemar is suitable as an alternative or Complementary Cancer Treatment and can assist or replace traditional forms such as Colon Cancer Treatment, Breast Cancer Treatment, Melanoma Cancer Treatment and leukaemia cancer treatment.
 
Health Sciences Institute, December 2005
Review-Article3-HSI-Dec-2005.pdf

4. Cancer: The 'Hail Mary' Miracle and More

Dr David Williams Alternatives, USA 2006 Review-Article4-Dr-David-William.pdf

5. Unplugging Cancer's Power Supply
' A unique fermented wheat germ extract (FWGE), Avemar, blocks glucose uptake within cancer cells, choking off their energy supply, reducing their ability to grow and prolife rate, and eventually causing cancer cell death by apoptosis, without any detrimental effect to healthy cells.'

Maureen Pelletier, MD, CCN, FACOG Anti-Aging Medical News, Summer 2008
Scientific paper - No58 Review-Article5-pdf58.pdf

6. Safety Studies Regarding a Standardized Extract of Fermented Wheat Germ.
 
'Clinical studies using Avemar [pulvis] as a supplement to drug therapy in cancer patients at doses of 8.5 g/day not only showed no evidence of toxicity, but also showed a reduction in the side effects of chemotherapy. Overall, it was concluded that Avemar [pulvis] would not be expected to cause adverse effects under the conditions of it's intended use as an ingredient in dietary supplements.'

International Journal of Toxicology Volume 26, Issue 3: 253-259. 2007.
Heimbach J T, Sebestyen Gy, Semjen G, Kennepohl E
Scientific Paper - No 52 Review-Article6-pdf52.pdf

 

BREAST CANCER

As an Alternative Cancer Treatment or a Complementary Cancer Treatment, Avemar will assist. These specific studies outline the benefits Avemar has to help with standard Breast Cancer Treatment. Some studies show that Avemar can be used in conjunction with Breast Cancer Treatment, whilst others show it can be used as an Alternative Cancer Treatment.

In-Vitro [laboratory]

Chemo-prevention with tamoxifen and Avemar by inducing apoptosis on MCF-7 (ER+) breast cancer cells.

'In conclusion it appears that supplementary therapy with Avemar in oestrogen receptor positive breast cancer may enhance the effect of Tamoxifen.'

2nd Congress of the World Society of Breast Health, Budapest, Hungary 24-28: 24-28. 2003. Tompa A, Kocsis Zs, Marcsek Z, Jakab M, Szende B, Hidvégi M:
Scientific Paper - No 33 Breast-Cancer1-pdf33.pdf

The Efficacy of Tamoxifen in Oestrogen Receptor-Positive Breast Cancer Cells Is Enhanced by a Medical Nutriment.

'As apoptosis increased when Avemar was added to tamoxifen treatment, the use of supplementary therapy with Avemar in the case of ER+ breast tumours may enhance the therapeutic effects of tamoxifen.'

Cancer Biotherapy & Radiopharmaceuticals 6: 746-753. 2004.
Marcsek Z, Kocsis Zs, Jakab M, Szende B, Tompa A:
Scientific Paper - No 39 Breast-Cancer2-pdf39.pdf
 
In-Vivo [animal studies]

Avemar inhibits the growth of mouse and human xenograft mammary carcinomas comparable to endocrine treatments.

'Conclusions: The tumor growth inhibitory effect of Avemar on ER positive MXT mouse breast carcinoma as well as in T47/D xenograft models are comparable (equal or better) to standard endocrine treatments. Avemar certainly did not reduce the effect of endocrine treatments. The antitumor activity of Avemar did not depend on the estrogen receptor status.'

Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 21132. 2007.
Tejeda M, Gaál D, Sz?cs I, Telekes A
Scientific Paper - No 51 Breast-Cancer3-pdf51.pdf

 

COLON CANCER

Colon cancer unfortunately affects millions of people around the globe and because of this effective Colon Cancer Treatment is sought by many. Research and studies of Colon Cancer Treatment has meant that many people can gain relief from this disease by using Avemar as a Complementary Cancer Treatment or as an alternative to mainstream therapies.
 
Specific studies via scientific tests confirm Avemar can be used as an Alternative Cancer Treatment or as a Complementary Cancer Treatment. Be it as an alternative or as a Complementary Cancer Treatment, Avemar use will ensure effective Colon Cancer Treatment is now available.
 
Human Study

A medical nutriment has supportive value in the treatment of colorectal cancer.
 
'Continuous supplementation of anticancer therapies with MSC for more than 6 months is beneficial to patients with colorectal cancer in terms of overall and progression-free survival.'
 
British Journal of Cancer 89: 465-469. 2003
Jakab F, Shoenfeld Y, Balogh Á, Nichelatti M, Hoffmann A, Kahán Zs, Lapis K, Mayer Á, Sápy P, Szentpétery F, Telekes A, Thurzó L, Vágvölgyi A, Hidvégi M:
Scientific Paper - No 32 Colon-Cancer1-pdf32.pdf

 
In-Vitro [laboratory]
 
Immunologic and Biochemical Effects of the Fermented Wheat Germ Extract Avemar.
 
'We conclude that we were able to identify new biochemical targets of Avemar; notably, the enzymes RR and COX. The inhibition of these enzymes results in the impressive antitumor effects observed with Avemar inpatients suffering from colon carcinoma.'
 
Biology and Medicine 230/2: 144-149. 2005.
Illmer C, Madlener S, Horvath Z, Saiko P, A. Losert, Herbacek I, Grusch M, Krupitza G, Fritzer-Szekeres M, Szekeres T Medical University of Vienna, Austria.
Scientific Paper - No 40 Colon-Cancer2-pdf40.pdf

 
In-Vivo [animal studies]
 
The effect of Avemar and Avemar + vitamin C on tumour growth and metastasis in experimental animals.
 
'[Avemar] lived up to our expectations, has indeed shown powerful biological activity, and proved able to stimulate the immune functions in hosts with severely impaired immune system. It has shown a powerful metastasis inhibiting effect in several tumour models without eliciting toxic side effects. It is our hope that this preparation will find a place in biotherapeutical treatment of human cancer.'
 
Anticancer Res 18: 2353-2358. 1998.
Hidvégi M, Rásó E, Tömösközi-Farkas R, Paku S, Lapis K, Szende B:
Scientific Paper - No 1 Colon-Cancer3-pdf1.pdf

MSC, [Avemar] a new benzoquinone-containing natural product with antimetastatic effect.
 
'Our in vitro and in vivo experiments with Avemar refer to a very significant anti-metastatic effect of this product observed in several animal experimental models. Most likely this effect correlates with the immune stimulatory effect manifested in both in vivo and in vitro tests, although the anti-proliferative, apoptotic, adhesion-related, as well as free radical-forming effects may all contribute to the fewer number of metastases, too.'
 
Cancer Biother Radiopharm 14: 277-289. 1999.
Hidvégi M, Rásó E, Tömösközi-Farkas R, Paku S, Lapis K, Szende B:
Scientific Paper - No 5 Colon-Cancer4-pdf5.pdf

Wheat germ extract inhibits experimental colon carcinogenesis in F-344 rats.
 
'It has been demonstrated for the first time that a wheat germ extract prevents colonic cancer in laboratory rats.'
 
Carcinogenesis 22: 1649-1652. 2001.
Zalatnai A, Lapis K, Szende B, Rásó E, Telekes A, Resetár Á, Hidvégi M:
Scientific Paper - No 15 Colon-Cancer5-pdf15.pdf


HEAD AND NECK CANCER

Human Studies
 
Recommendation of the Hungarian Society for Face, Mandible and Oral Surgery in the indication of supportive therapy with Avemar.
 
'For patients suffering from head - and neck tumours - primarily malignant cancer of the oral cavity, the progression of the disease can be slowed significantly, the five-year survival rate increased considerably, the quality of life improved, and the oxidative stress on the patients reduced by the long-term application of the supplementary formula Avemar. The Association considers the supportive treatment with the formula Avemar as an important part of the complex therapeutic protocols applied in stages II, III and IV of malignant cancer of the oral cavity.'
 
Orvosi Hetilap, Hungarian Medical Journal 147(35): 1709-11. 2006.
Barabas J, Nemeth Z
Scientific Paper - No 47 Head-Neck-Cancer1-47pdf.pdf

A multicentric prospective open trial on the quality of life and oxidative stress in patients affected by advanced head and neck cancer treated with a new benzoquinone-rich product derived from fermented wheat germ (Avemar).
 
'the reduction in free oxygen radicals induced by [Avemar] is correlated with a clinically significant improvement in the quality of life in patients with advanced [head and neck] cancer'.
 
Mediterr J Nutr Metab : 37-42. 2008.
Sukkar GS, Cella F, Rovera G, Nichelatti M, Ragni G, Chiavenna G, Giannoni R, Ferrari C.
Scientific Paper - No 54 Head-Neck-Cancer2-54pdf.pdf


GASTRIC CANCER

Cytotoxic activities of fermented wheat germ extract (Avemar) on human gastric carcinoma cells by induction of apoptosis.

'Avemar was found to dose-dependently inhibit the growth of gastric carcinoma cells possibly via an apoptosis-dependent pathway and has a potential to be an additive or synergistic effect with cytotoxic agents.'

2005 ASCO Annual Meeting Abstract No: 4254. 2005.
S. N. Lee, H. Park, K. E. Lee:
Scientific Paper - No 45 Gastric-Cancer1-45.pdf


LEUKAEMIA

Like breast cancer, leukaemia is a recognisable form of cancer that affects bone marrow and usually results in intense treatment regimes. Traditional leukaemia cancer treatment usually involves pharmaceutical medications, radiation therapy and in some cases bone marrow transplant.

Unfortunately many men, women and children are affected by leukaemia and require many forms of leukaemia cancer treatment. Research and studies of leukaemia cancer treatment has meant that patients can gain relief from this disease by using Avemar as a Complementary Cancer Treatment or as an alternative to mainstream therapies.

Specific studies via scientific tests confirm Avemar can be used as an Alternative Cancer Treatment or as a Complementary Cancer Treatment. Be it as an alternative or a Complementary Cancer Treatment, Avemar use will ensure effective leukaemia cancer treatment is now available.

In-Vitro [laboratory]

Avemar, a nontoxic fermented wheat germ extract, induces apoptosis and inhibits ribonucleotide reductase in human HL-60 promyelocytic leukemia cells.

'We conclude that Avemar might be a promising additional option for combination treatment of human leukemia.'

Cancer Letters 250/2: 323-328. 2007.
Saiko P, Ozsvar-Kozma M, Madlener S, Bernhaus A, Lackner A, Grusch M, Horvath Zs, Krupitza G, Jaeger W, Ammer K, Fritzer-Szekeres M, Szekeres T
Scientific Paper - No 48 Leukaemia1-pdf48.pdf

 
Changes in the kinase expression panel of K562 human leukemia after Avemar treatment.
 
Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings Part I. Vol 25, No. 18S (June 20 Supplement), 2007: 14143. 2007.
Telekes A, Rásó E
Scientific Paper - No 50 Leukaemia2-pdf50.pdf

 
Fermented wheat germ extract inhibits glycolysis/pentose cycle enzymes and induces apoptosis through poly (ADP-ribose) polymerase activation in Jurkat T-cell leukemia tumor cells.

'In conclusion, Avemar is a natural fermented wheat germ extract with no known toxicities, and it is a strong regulator of leukemia tumor cell macromolecule synthesis, cell cycle progression, apoptosis, and proliferation. Avemar regulates metabolic enzymes that are involved in glucose carbon redistribution between proliferation-related structural and functional macromolecules (RNA, DNA). Avemar treatment results in profound intracellular metabolic changes that bring devastating consequences for the proliferation of leukemia cells of the lymphoid lineage.'

J Biol Chem 277: 46408-46414. 2002.
Comín-Anduix B, Boros L. G, Marin S, Boren J, Callol-Massot C, Centelles J. J, Torres J. L, Agell N, Bassilian S, Cascante M: University of Barcelona, Spain
Scientific Paper - No 30 Leukaemia3-pdf30.pdf

 
Synergistic Effect of Avemar on Proinflammatory Cytokine Production and Ras-Mediated Cell Activation.

'Myeloid cells (here P388D mouse myeloid leukemia cells) showed very strong growth inhibition and decreased survival in the presence of Avemar'

András Telekes, Endre Kiss-Tóth, Tünde Nagy:
Ann. N.Y. Acad. Sci. 1051: 515-528. 2005.
Scientific Paper - No 43 Leukaemia4-pdf43.pdf

 
Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines.

Int J Oncol 20: 563-570. 2002.
Fajka-Boja R, Hidvégi M, Shoenfeld Y, Ion G, Demydenko D, Tömösközi-Farkas R, Vizler Cs, Telekes A, Resetár Á, Monostori É:
Scientific Paper - No 26 Leukaemia5-pdf26.pdf


LUNG CANCER

In-Vitro [laboratory]

The effect of Avemar and Avemar + vitamin C on tumour growth and metastasis in experimental animals.

'[Avemar] lived up to our expectations, has indeed shown powerful biological activity, and proved able to stimulate the immune functions in hosts with severely impaired immune system. It has shown a powerful metastasis inhibiting effect in several tumour models without eliciting toxic side effects. It is our hope that this preparation will find a place in bio-therapeutical treatment of human cancer.'

Anticancer Res 18: 2353-2358. 1998.
Hidvégi M, Rásó E, Tömösközi-Farkas R, Paku S, Lapis K, Szende B:
Scientific Paper - No 1 Lung-Cancer1-pdf1.pdf

 
MSC, [Avemar] a new benzoquinone-containing natural product with anti-metastatic effect.

'Our in vitro and in vivo experiments with Avemar refer to a very significant anti-metastatic effect of this product observed in several animal experimental models. Most likely this effect correlates with the immune stimulatory effect manifested in both in vivo and in vitro tests, although the anti-proliferative, apoptotic, adhesion-related, as well as free radical-forming effects may all contribute to the fewer number of metastases, too.

Cancer Biother Radiopharm 14: 277-289. 1999.
Hidvégi M, Rásó E, Tömösközi-Farkas R, Lapis K, Szende B:
Scientific Paper - No 5
Lung-Cancer2-pdf5.pdf


LYMPHOMA

In-Vivo [animal studies]

Avemar, a nontoxic fermented wheat germ extract, attenuates the growth of sensitive and 5-FdUrd/Ara-C cross-resistant H9 human lymphoma cells through induction of apoptosis.

'Regarding our results, we conclude that Avemar is able to overcome 5-FdUrd/Ara-C cross-resistance in H9 human lymphoma cells and induces dose-dependent apoptosis. Additionally, this non-toxic fermented wheat germ extract exerts it's cytotoxicity without causing remarkable cell cycle perturbations in both sensitive and cross-resistant H9 cells.'

Oncology Reports Vol 21, No. 3: 787-791. 2009.
Saiko P, Ozsvar-Kozma M, Graser G, Lackner A, Grusch M, Madlener S, Krupitza G, Jaeger W, Hidvegi M, Agarwal R.P, Fritzer-Szekeres M, Szekeres T
Scientific Paper - No 59 Lymphoma1-pdf59.pdf

 
Fermented wheat germ extract induces apoptosis and downregulation of major histocompatibility complex class I proteins in tumor T and B cell lines.

International Journal Oncology 20: 563-570. 2002.
Fajka-Boja R, Hidvégi M, Shoenfeld Y, Ion G, Demydenko D, Tömösközi-Farkas R, Vizler Cs, Telekes A, Reset?r Á,Monostori É:
Scientific Paper - No 26 Lymphoma2-pdf26.pdf


MELANOMA

Melanoma is a type of cancer that affects people of all ages. This skin cancer is a common, and recognisable form of cancer. Malignant melanoma tumours are responsible for 75% of all deaths related to skin cancer. Like other forms of cancer, Melanoma Cancer Treatment can result in radiation therapy, chemotherapy and surgery, which can be dangerous and harmful to the body.

Unfortunately many people around the world are affected by skin melanomas and require many forms of Melanoma Cancer Treatment. Research and studies of Melanoma Cancer Treatment has meant that patients can gain relief from the terrible disease by using Avemar as a Complementary Cancer Treatment or as an alternative to mainstream therapies.

Specific studies via scientific tests confirm Avemar can be used as an Alternative Cancer Treatment or as a Complementary Cancer Treatment. Be it as an alternative or Complementary Cancer Treatment, Avemar use will ensure effective Melanoma Cancer Treatment is now available.

Human Studies

Adjuvant Fermented Wheat Germ Extract (Avemar) Nutraceutical Improves Survival of High-Risk Skin Melanoma Patients: A Randomized, Pilot, Phase II Clinical Study with a 7-Year Follow-Up.

'We, therefore, highly recommend the inclusion of this fermented wheat-germ-extract-based medical nutriment into the adjuvant protocols of high risk skin melanoma patients. We also encourage colleagues worldwide to further test this nontoxic active preparation in melanoma and in other types of human cancers.'

Cancer Biother Radiopharm Volume 23, Issue 4.: 477-482. 2008
Demidov L. V, Manziuk L. V, Kharkevitch G. Y; Pirogova, N. A; Artamonova, E. V :
Scientific Paper - No 55 Melanoma1-pdf55.pdf

 
The antimetastatic effect of Avemar in high-risk melanoma patients. 18th UICC International Cancer Congress.

'These preliminary data show that combination of routine DTIC chemotherapy and AVEMAR? may decrease risk of relapse and postpone time of melanoma progression. The published preclinical results suggest that the anti-metastatic effect of AVEMAR? is related to its cell adhesion inhibitory, cell proliferation inhibitory, apoptosis enhancing and antioxidant characteristics.'

Oslo, Norway. 30. June - 5. July 2002. (Abstract) Int J Cancer 100(S13): 408. 2002. Demidov L. V, Manzjuk L. V, Kharkevitch G. Y, Artamonova E. V, Pirogova N. A: Scientific Paper - No 28 Melanoma2-pdf28.pdf

 
In-Vitro [laboratory]

The effect of Avemar and Avemar + vitamin C on tumour growth and metastasis in experimental animals.

'[Avemar] lived up to our expectations, has indeed shown powerful biological activity, and proved able to stimulate the immune functions in hosts with severely impaired immune system. It has shown a powerful metastasis inhibiting effect in several tumour models without eliciting toxic side effects. It is our hope that this preparation will find a place in biotherapeutical treatment of human cancer.'

Anticancer Res 18: 2353-2358. 1998.
Hidvégi M, Rásó E, Tömösközi-Farkas R, Paku S, Lapis K, Szende B:
Scientific Paper - No 1 Melanoma3-pdf1.pdf

 
MSC, [Avemar] a new benzoquinone-containing natural product with antimetastatic effect.

'Our in vitro and in vivo experiments with Avemar refer to a very significant anti-metastatic effect of this product observed in several animal experimental models. Most likely this effect correlates with the immune stimulatory effect manifested in both in vivo and in vitro tests, although the anti-proliferative, apoptotic, adhesion-related, as well as free radical-forming effects may all contribute to the fewer number of metastases, too.'

Cancer Biother Radiopharm 14: 277-289. 1999.
Hidvégi M, Rásó E, Tömösközi-Farkas R, Lapis K, Szende B:
Scientific Paper - No 5 Melanoma4-pdf5.pdf

 

PANCREATIC CANCER

In-Vitro [laboratory]

Wheat germ extract decreases glucose uptake and RNA ribose formation but increases fatty acid synthesis in MIA pancreatic adenocarcinoma cells.

Pancreas 23: 141-147. 2001.
Boros L. G, Lapis K, Szende B, Tömösközi-Farkas R, Balogh Á, Boren J, Marin S, Cascante M, Hidvégi M:
Scientific Paper - No 10 Pancreatic-Cancer1-pdf10.pdf
 
A metabolic hypothesis of cell growth and death in pancreatic cancer.

'Conclusion: Evidence is presented that demonstrates opposite changes in metabolic phenotypes induced by TGF-B, a cell-transforming agent, and tumour growth-inhibiting phytochemicals such as genistein and Avemar, or novel synthetic anti-leukemic drugs such as STI571 (Gleevec). Intermediary metabolic enzymes that mediate the growth signalling pathways and promote malignant cell transformation may serve as high efficacy non-genetic novel targets for cancer therapies.'

Pancreas 24: 26-33. 2002.
Boros L. G, Lee W-N. P, Go V. L. W:
Scientific Paper - No 25 Pancreatic-Cancer2-pdf25.pdf

»ó±â ³Ä¿ë¿¡ ´ëÇÑ ±â°è ¹ø¿ªÀ̹ǷΠ¾î»öÇÑ Ç¥ÇöÀÌ ÀÖÀ»Áö ¸ð¸¨´Ï´Ù. ¾çÇØ ¶ø´Ï´Ù.

À¯¹æ¾Ï
´ëü ¾Ï Ä¡·á ¶Ç´Â º¸¿Ï ¾Ï Ä¡·á·Î Avemar°¡ Áö¿øÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ±¸Ã¼ÀûÀÎ ¿¬±¸´Â Avemar°¡ Ç¥ÁØ À¯¹æ¾Ï Ä¡·á¸¦ Áö¿øÇؾßÇÏ´Â ÀåÁ¡À» ¼³¸í. ÀϺΠ¿¬±¸´Â Avemar´Â À¯¹æ¾Ï Ä¡·á¿Í ÇÔ²² »ç¿ëÇÒ ¼ö ÀÖ´Ù´Â °ÍÀ» º¸¿© ÇÑÆí ´Ù¸¥ ´ë¾ÈÀº ±×°ÍÀÌ ¾Ï Ä¡·á·Î »ç¿ëµÉ ¼ö ÀÖ´Ù´Â °ÍÀ» º¸¿©ÁØ´Ù.

ü¿Ü [¿¬±¸½Ç]

MCF-7 ¼¼Æ÷ »ç¸êÀ» À¯µµÇÏ¿© Ÿ¸ñ½ÃÆæ°ú Avemar¿Í È­ÇÐ ¿¹¹æ (ER +) À¯¹æ¾Ï ¼¼Æ÷.

"°á·ÐÀº ¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾ÏÀÇ Avemar¿Í º¸Á¶ ¿ä¹ýÀº Ÿ¸ñ½ÃÆæÀÇ È¿°ú¸¦ ³ôÀÏ ¼ö ÀÖ´Ù°í »ý°¢µÈ´Ù. '

À¯¹æ °Ç°­ ¼¼°è ÇÐȸ Á¦ 2 ȸ ÀÇȸ, ºÎ´ÙÆ佺Ʈ, Çë°¡¸® 24-28:24-28. 2003. µ¿ÆÄ A, ½Ã½º Zs´Â Marcsek Z, ÀðÄ«ºÎ M, Szende B, HidvégiM :
°úÇÐ ³í¹® - ¾Æ´Ï 33 ¸ðÀ¯ Cancer1-pdf33.pdf

¿¡½ºÆ®·Î°Õ ¼ö¿ëü ¾ç¼º À¯¹æ¾Ï ¼¼Æ÷¿¡¼­ Ÿ¸ñ½ÃÆæÀÇ È¿°ú´Â ÀÇ·á ¿µ¾ç ÀÇÇØ °­È­µÇ°í ÀÖ½À´Ï´Ù.
'¾ÆÆ÷Åä½Ã½º°¡ Avemar°¡ Ä¡·á¸¦ Ÿ¸ñ½ÃÆæ¿¡ Ãß°¡ µÉ ¶§ Áõ°¡ÇÔ¿¡ µû¶ó ER + À¯¹æ¾ÏÀÇ °æ¿ì Avemar°ú º¸Ãæ ¿ä¹ýÀÇ »ç¿ëÀº Ÿ¸ñ½ÃÆæÀÇ Ä¡·á È¿°ú¸¦ ³ôÀÏ ¼öÀÖ´Ù. '

¾Ï »ý¹° ¿ä¹ý°ú ¹æ»ç¼º ÀǾàÇ° 6:746À¸·ÎºÎÅÍ 753. 2004 ³â.
Marcsek Z, ½Ã½º Zs´Â ÀðÄ«ºÎ M, Szende B, µ¿ÆÄ A :
°úÇÐ ³í¹® - ¾Æ´Ï 39 ¸ðÀ¯ Cancer2-pdf39.pdf

»ýü [µ¿¹° ½ÇÇè]
Avemar ³»ºÐºñ ¿ä¹ý¿¡ ÇÊÀûÇÏ´Â ¸¶¿ì½º ¹× Àΰ£ À¯¹æ¾Ï ÀÌÁ¾ À̽ÄÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÑ´Ù.

°á·Ð : Á¾¾ç Áõ½Ä ¾ïÁ¦ ER ¾ç¼º MXT ¸¶¿ì½º À¯¹æ¾Ï¿¡ ´ëÇÑ AvemarÀÇ È¿°ú¿Í ¸¶Âù°¡Áö·Î T47 / D ÀÌÁ¾ ÀÌ½Ä ¸ðµ¨Àº Ç¥ÁØ ³»ºÐºñ Ä¡·á »óÀÀ (µ¿µîÇÏ​​°Å³ª ±× ÀÌ»ó)ÀÌ´Ù. Avemar È®½ÇÈ÷ ³»ºÐºñ Ä¡·áÀÇ È¿°ú¸¦ °¨¼Ò½ÃÅ°Áö ¾Ê¾Ò´Ù. AvemarÀÇ Ç× Á¾¾ç È°¼ºÀº ¿¡½ºÆ®·Î°Õ ¼ö¿ëüÀÇ »óÅ¿¡ ÀÇÁ¸ÇÏÁö ¾Ê¾Ò½À´Ï´Ù. '

Journal of Clinical Oncology Àú³Î 2007 ³â ASCO ¿¬·Ê ȸÀÇ È¸ÀÇ·Ï ÆÄÆ® I. ±Ç 25 È£ 18S (6 ¿ù 20 ÀÏ º¸Ãæ) 2007 ³â : 21132. 2007 ³â.
Å×Çì´Ù M, Çϸ£ D, SzÀÇ? CS I, Telekes
°úÇÐ ³í¹® - ¾Æ´Ï 51 ¸ðÀ¯ Cancer3-pdf51.pdf


´ëÀå ¾Ï
´ëÀå ¾ÏÀº ºÒÇàÈ÷µµ Àü¼¼°è ¼ö¹é¸¸ ¸íÀÇ »ç¶÷µé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°íÀÌ È¿°úÀûÀÎ ´ëÀå ¾ÏÀÇ Ä¡·á¿¡´Â ¸¹Àº »ç¶÷µéÀÌ ¿ä±¸µÇ°íÀÖ´Ù. ´ëÀå ¾Ï Ä¡·áÀÇ ¿¬±¸´Â ¸¹Àº »ç¶÷µéÀÌ »óÈ£ º¸¿ÏÀûÀÎ ¾Ï Ä¡·á·Î¼­ ȤÀº ÁÖ·ù Ä¡·á¹ýÀÇ ´ë¾ÈÀ¸·Î Avemar¸¦ »ç¿ëÇÏ¿©ÀÌ Áúº´¿¡¼­ ±¸Á¦¸¦ ¾òÀ» ¼öÀÖ´Â °ÍÀ» ÀǹÌÇÏ°íÀÖ´Ù .

Avemar È®ÀÎ °úÇÐÀûÀÎ Å×½ºÆ®¸¦ ÅëÇØ Æ¯Á¤ ¿¬±¸´Â ´ëü ¾Ï Ä¡·á·Î¼­ ȤÀº º¸¿Ï ¾Ï Ä¡·á·Î »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ë¾ÈÀ¸·Î ¶Ç´Â º¸¿Ï ¾Ï Ä¡·á·Î Àú°ÍÀÌ´Ù, Avemar »ç¿ëÀÌ È¿°úÀûÀÎ ´ëÀå ¾Ï Ä¡·á´Â ÇöÀç »ç¿ëÇÒ ¼ö ÀÖ´ÂÁö È®ÀÎÇÕ´Ï´Ù.

ÀÎü ¿¬±¸

ÀÇ·á Àھ繰Àº ´ëÀå ¾ÏÀÇ Ä¡·á¿¡ Áö¿øÇÏ´Â °ªÀ» °¡Áø´Ù.

'6 °³¿ù ÀÌ»óÀ» À§ÇØ MSC¿Í Ç×¾Ï Ä¡·á¸¦ °è¼Ó º¸±ÞÀº Àüü ¹× ¹« ÁøÇà »ýÁ¸ ±â°£¸é¿¡¼­ ´ëÀå ¾Ï È¯ÀÚ¿¡°Ô À¯ÀÍÇÏ´Ù. '

¾Ï 89ÀÇ ¿µ±¹ ÀüÇ¥ : 465¿¡¼­ 469. 2003
ÀðÄ«ºÎ F, Shoenfeld Y, ¹Ù·Î±¸ Á, Nichelatti M È£ÇÁ¸¸ A, ÇÏ¹Ý Zs´Â ¶óÇǽº K, ¸ÞÀ̾î Á, SápyP, SzentpéteryF, Telekes A, ThurzóL, VágvölgyiA, HidvégiM :
°úÇÐ ³í¹® - ¾Æ´Ï 32 ÄÝ·Ð Cancer1-pdf32.pdf


ü¿Ü [¿¬±¸½Ç]

¸é¿ª°ú ¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹° AvemarÀÇ »ýÈ­ÇÐ Àû ¿µÇâ.

ƯÈ÷ È¿¼Ò RR°ú COX; '¿ì¸®´Â AvemarÀÇ »õ·Î¿î »ýÈ­ È®ÀûÀΠǥÀûÀ» ½Äº° ÇÒ ¼ö ÀÖ¾ú´Ù°í °á·Ð ³»¸°´Ù. °áÀå¾ÏÀ» ¾Î°í Avemar ÀÔ¿ø ȯÀÚ¿¡¼­ °üÂû µÈ ÀλóÀûÀÎ Ç× Á¾¾ç È¿°úÀÇ ÀÌ·¯ÇÑ È¿¼ÒÀÇ ¾ïÁ¦. '

»ý¹°ÇÐ ¹× ÀÇÇÐ 2 ºÐ 230:144-149. 2005 ³â.
Illmer C, Madlener S, È£¸£ ¹Ù½º Z, ¼­È£ P, A. Losert, Herbacek I, Grusch M, Krupitza G, Fritzer-Á¬Ä«Áî M, ºñ¿£³ª, ¿À½ºÆ®¸®¾ÆÀÇ Á¬Ä«Áî T ÀÇ°ú ´ëÇÐ.
°úÇÐ ³í¹® - ¾Æ´Ï 40 ÄÝ·Ð Cancer2-pdf40.pdf


»ýü [µ¿¹° ½ÇÇè]

½ÇÇè µ¿¹°ÀÇ Á¾¾ç ¼ºÀå°ú ÀüÀÌ¿¡ Avemar¿Í Avemar + ºñŸ¹Î CÀÇ È¿°ú.

'[Avemar] ¿ì¸®ÀÇ ±â´ë¿¡ »ì¾Ò´ø È®½ÇÈ÷ °­·ÂÇÑ »ý¹° È°¼ºÀ» º¸ÀÎÀÖ¾î ½É°¢ÇÑ Àå¾Ö ¸é¿ª ü°è¸¦ °¡Áø È£½ºÆ®ÀÇ ¸é¿ª ±â´ÉÀ» ÀÚ±ØÇÏ´Â °ÍÀÌ Áõ¸íµÇ°í ÀÖ½À´Ï´Ù. ±×°ÍÀº µ¶¼º ºÎÀÛ¿ëÀ» À¯¹ßÇÏÁö ¾Ê°í ¿©·¯ Á¾¾ç ¸ðµ¨¿¡¼­ °­·ÂÇÑ ÀüÀÌ ¾ïÁ¦ È¿°ú¸¦ º¸¿© ÁÖ¾ú´Ù. ÀÌ°ÍÀº Áغñ°¡ Àΰ£ÀÇ ¾Ï biotherapeutical Ä¡·á Àå¼Ò¸¦ ãÀ» °ÍÀ» ¹Ù¶ó°í ÀÖ½À´Ï´Ù. '

Ç×¾Ï ÇØ»óµµ 18:2353 ³â¿¡¼­ 2358 ³â. 1998.
HidvégiM, RASO E, Tömösközi-FarkasÀÇ R, ¹ÚÁö¼º S, ¶óÇǽº K, Szende B :
°úÇÐ ³í¹® - ¾Æ¹«µµ ÄÝ·Ð Cancer3-pdf1.pdf

MSC, Avemar] Ç× ÀüÀÌ È¿°ú¸¦ °¡Áø »õ·Î¿î º¥Á¶ Äû³í ÇÔÀ¯ õ¿¬¹°.

'¿ì¸®ÀÇ in vitro ¹× in Avemar¸¦ ÀÌ¿ëÇÑ in vivo ½ÇÇè¿¡¼­ ÀϺΠµ¿¹° ½ÇÇè ¸ðµ¨¿¡¼­ °üÂû µÈÀÌ Á¦Ç°ÀÇ ¸Å¿ì Áß¿äÇÑ Ç× ÀüÀÌ È¿°ú¸¦ ÂüÁ¶ÇϽʽÿÀ. ´ëºÎºÐÀÇ °æ¿ìÀÌ È¿°ú´Â Ç× Áõ½Ä, ¼¼Æ÷ »ç¸ê, Á¢Âø °ü·ÃÇßÀ¸³ª ¹× ÀÚÀ¯ ¶óµðÄ®À» Çü¼ºÇÏ´Â È¿°ú´Â ¸ðµç ÀüÀÌ ¼Ò¼ö¿¡ ±â¿©ÇÒ ¼öÀÖ´Â in vivo ¹× in vitro ½ÃÇè ¸ðµÎ¿¡ ³ªÅ¸³ª´Â ¸é¿ª ÀÚ±Ø È¿°ú¿Í ¿¬°ü ³Ê¹«. '

¾Ï Biother Radiopharm 14:277¿¡¼­ 289. 1999.
HidvégiM, RASO E, Tömösközi-FarkasÀÇ R, ¹ÚÁö¼º S, ¶óÇǽº K, Szende B :
°úÇÐ ³í¹® - ¾Æ´Ï 5 ÄÝ·Ð Cancer4-pdf5.pdf
¹Ð ¹è¾Æ ÃßÃâ¹°Àº F-344 ÁãÀÇ ¹ß¾Ï ½ÇÇè ÄÝ·ÐÀ» ÀúÇØÇÑ´Ù.

'ÀÌ°ÍÀº ¹Ð ¹è¾Æ ÃßÃâ¹°Àº ½ÇÇè Áã¿¡ °áÀå¾ÏÀ» ¹æÁöÇÏ´Â °ÍÀº À̹øÀÌ Ã³À½ ÀÔÁõµÆ´Ù. '

¹ß¾Ï 22:1649 ³â¿¡¼­ 1652 ³â. 2001.
Zalatnai A, ¶óÇǽº K, Szende B, RASO E, Telekes A, ResetárÁ, HidvégiM :
°úÇÐ ³í¹® - ¾Æ´Ï 15 ÄÝ·Ð Cancer5-pdf15.pdf

¸Ó¸®¿Í ¸ñ ¾Ï
Àΰ£ ÇкÎ

Avemar°úÁöÁö ¿ä¹ýÀÇ ÀûÀÀÁõÀÇ ¾ó±¼, ¾Æ·¡ ÅλÀ¿Í ±¸°­ ¿Ü°ú¸¦À§ÇÑ Çë°¡¸® ÇÐȸ ±Ç°í.

¸Ó¸®¿¡ ÀÌȯµÇ´Â ȯÀÚÀÇ °æ¿ì - Àڱà °æºÎ Á¾¾ç - ±¸°­ ÁÖ·Î ¾Ç¼º ¾Ï, Áúº´ÀÇ ÁøÇàÀÌ ÇöÀúÇÏ°Ô ´ÊÃâ ¼ö ÀÖÀ¸¸ç, 5 ³â »ýÁ¸À²Àº Å©°Ô °³¼± »îÀÇ ÁúÀ» Áõ°¡½ÃÄÑ À§ÀÇ »êÈ­ ½ºÆ®·¹½º ȯÀÚ´Â º¸Á¶ ½Ä AvemarÀÇ Àå±âÀûÀÎ ÀÀ¿ë ÇÁ·Î±×·¥¿¡¼­ °¨¼ÒÇß´Ù. Çùȸ´Â ±¸°­ÀÇ ¾Ç¼º ¾ÏÀÇ ´Ü°è II, III ¹× IV¿¡ Àû¿ë º¹ÀâÇÑ Ä¡·á ÇÁ·ÎÅäÄÝÀÇ Áß¿äÇÑ ÀÏȯÀ¸·Î ¼ö½Ä Avemar°úÁöÁö ¿ä¹ýÀ» °í·ÁÇÕ´Ï´Ù. '

Orvosi Hetilap, Çë°¡¸® ÀÇÇÐ Àú³Î 147 (35) : 1709 ³â¿¡¼­ 1711 ³â. 2006 ³â.
Barabas J, ³×¸ÞÅä Z
°úÇÐ ³í¹® - ¾Æ´Ï 47 Çìµå ³Ø Cancer1-47pdf.pdf

¹ßÈ¿ µÈ ¹Ð ¹è¾Æ (Avemar)¿¡¼­ ÆÄ»ý µÈ »õ·Î¿î º¥Á¶ Äû³í dzºÎÇÑ Á¦Ç° ó¸® ÁøÇà ¸Ó¸®¿Í ¸ñ ¾ÏÀÇ ¿µÇâÀ»¹ÞÀº ȯÀÚÀÇ »ýÈ°°ú »êÈ­ ½ºÆ®·¹½ºÀÇ Áú¿¡ ´Ù Áß½ÉÀÇ ±àÁ¤Àû ¿ÀÇ ½ÃÇè.

'¿¡ ÀÇÇØ À¯µµ µÈ À¯¸® »ê¼Ò ¶óµðÄ®ÀÇ °¨¼Ò [Avemar] °í±Þ [¸Ó¸®¿Í ¸ñ] ¾Ï ȯÀÚÀÇ »îÀÇ ÁúÀ» ÀÓ»ó ÀûÀ¸·Î ÀǹÌÀÖ´Â °³¼±°ú »ó°ü °ü°è'.

Mediterr J NUTR Metab :37-42. 2008 ³â.
Sukkar GS ¼¼¶ó F, Rovera G, Nichelatti M, ÆĿöó G, Å°¾Æ붼³ª G, Giannoni º¸³½ R, Æä¶ó¸® C.
°úÇÐ ³í¹® - ¾Æ´Ï 54 Çìµå ³Ø Cancer2-54pdf.pdf

À§¾Ï
apoptosisÀÇ À¯µµ¿¡ ÀÇÇÑ Àΰ£ À§¾Ï ¼¼Æ÷ÀÇ ¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹° (Avemar)ÀÇ ¼¼Æ÷ »óÇØ È°¼º.

'Avemar´Â ¿ë·® ÀÇÁ¸ÀûÀ¸·Î ¼¼Æ÷ »ç¸ê ÀÇÁ¸¼º °æ·Î¸¦ ÅëÇØ ¾Æ¸¶ À§¾Ï ¼¼Æ÷ÀÇ ¼ºÀåÀ» ¾ïÁ¦ÇÏ´Â °ÍÀ» ¹ß°ß ¹× ¼¼Æ÷ µ¶¼º Á¦¿Í ÷°¡Á¦ ¶Ç´Â ½Ã³ÊÁö È¿°ú ÀÏ °¡´É¼ºÀ» Áö´Ï°íÀÖ¾ú½À´Ï´Ù. '

2005 ³â ASCO ¿¬·Ê ȸÀÇÀÇ Ãß»ó ¹øÈ£ : 4254. 2005 ³â.
S. N. ¸®, H. °ø¿ø, K. E. ¸® :
°úÇÐ ³í¹® - ¾Æ´Ï 45 À§ Cancer1-45.pdf


¹éÇ÷º´
À¯¹æ¾Ï°ú ¸¶Âù°¡Áö·Î ¹éÇ÷º´Àº °ñ¼ö¿Í °­·ÄÇÑ Ä¡·á¿¡¼­ ÀϹÝÀûÀ¸·Î °á°ú¿¡ ¿µÇâÀ» ¹ÌÄ¡´Â ¾Ï ¾Ë¾Æº¼ ¼öÀÖ´Â ¸ð¾çÀÌ´Ù. ÀüÅë ¹éÇ÷º´ ¾Ï Ä¡·á´Â ÀϹÝÀûÀ¸·Î ÀǾà ÀÇÇÐ, ¹æ»ç¼± ¿ä¹ý ¹× °æ¿ì¿¡ µû¶ó¼­´Â °ñ¼ö À̽ÄÀ» µ¿¹ÝÇÑ´Ù.

ºÒÇàÇÏ°Ôµµ ¸¹Àº ³²¼º, ¿©¼º°ú ¾î¸°ÀÌ´Â ¹éÇ÷º´ÀÇ ¿µÇâÀ» ¹Þ¾Æ ¹éÇ÷º´, ¾Ï Ä¡·áÀÇ ¿©·¯ ÇüŸ¦ ÇÊ¿ä·ÎÇÕ´Ï´Ù. ¹éÇ÷º´ ¾Ï Ä¡·áÀÇ ¿¬±¸´Â ȯÀÚ°¡ º¸¿Ï ¾Ï Ä¡·á·Î¼­ ȤÀº ÁÖ·ù Ä¡·á¹ýÀÇ ´ë¾ÈÀ¸·Î Avemar¸¦ »ç¿ëÇÏ¿©ÀÌ Áúº´¿¡¼­ ±¸Á¦¸¦ ¾òÀ» ¼öÀÖ´Â °ÍÀ» ÀǹÌÇÏ°íÀÖ´Ù.

Avemar È®ÀÎ °úÇÐÀûÀÎ Å×½ºÆ®¸¦ ÅëÇØ Æ¯Á¤ ¿¬±¸´Â ´ëü ¾Ï Ä¡·á·Î¼­ ȤÀº º¸¿Ï ¾Ï Ä¡·á·Î »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ëü ¶Ç´Â º¸¿ÏÀûÀÎ ¾Ï Ä¡·á·Î ¹Ýµå½Ã Avemar »ç¿ëÀÌ È¿°úÀûÀÎ ¹éÇ÷º´ ¾Ï Ä¡·á´Â ÇöÀç »ç¿ëÇÒ ¼ö ÀÖ´ÂÁö È®ÀÎÇÕ´Ï´Ù.

ü¿Ü [¿¬±¸½Ç]

Avemar, ºñ µ¶¼º ¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹°Àº apoptosis¸¦ À¯µµÇÏ°í Àΰ£ HL-60 Àü °ñ¼ö ¹éÇ÷º´ ¼¼Æ÷¿¡¼­ ¸®º¸ ´ºÅ¬·¹¿ÀƼµå ȯ¿ø È¿¼Ò¸¦ ¾ïÁ¦ÇÑ´Ù.

'¿ì¸®´Â Avemar´Â Àΰ£ ¹éÇ÷º´ÀÇ º´¿ë ¿ä¹ýÀ»À§ÇÑ À¯¸ÁÇÑ Ãß°¡ ¿É¼ÇÀÌ ÀÖÀ»Áöµµ ¸ð¸¥´Ù°í °á·Ð ³»¸°´Ù. '

¾ÏÀÇ ÆíÁö 2 ºÐ 250:323-328. 2007 ³â.
¼­È£ P, Ozsvar-ÄÚÁ M, Madlener S, Bernhaus A, ¶ùÄí³ª A, Grusch M, È£¸£ ¹Ù½º Zs´Â Krupitza G, Àç±Ô¾î W, ¾Æ¹«¸£ K, Fritzer-Á¬Ä«Áî M, Á¬Ä«Áî T
°úÇÐ ³í¹® - ¾Æ´Ï 48 Leukaemia1-pdf48.pdf


Avemar ó¸® ÈÄ K562 Àΰ£ ¹éÇ÷º´ Å°´Ï ¾ÆÁ¦ ¹ßÇö ÆгΠº¯°æ.

Journal of Clinical Oncology Àú³Î 2007 ³â ASCO ¿¬·Ê ȸÀÇ È¸ÀÇ·Ï ÆÄÆ® I. ±Ç 25 È£ 18S (6 ¿ù 20 ÀÏ Ãß°¡) 2007:14143. 2007 ³â.
Telekes A, RASO E
°úÇÐ ³í¹® - ¾Æ´Ï 50 Leukaemia2-pdf50.pdf


¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹°Àº ÇØ´ç ºÐÇØ / ÆæÆ® ½º »çÀÌŬ È¿¼Ò¸¦ ¾ïÁ¦ÇÏ°í Àú ÄÆ T ¼¼Æ÷ ¹éÇ÷º´ Á¾¾ç ¼¼Æ÷ÀÇ Æú¸® (ADP-¸®º¸¿À½º) ÁßÇÕ È¿¼ÒÀÇ È°¼ºÈ­¸¦ ÅëÇØ ¼¼Æ÷ »ç¸êÀ» À¯µµÇÑ´Ù.
"°á·ÐÀûÀ¸·Î, Avemar´Â ¾Ë·ÁÁ® ÀÖÁö ¾ÊÀº µ¶¼º õ¿¬ ¹ßÈ¿ ¸Æ¾Æ ÃßÃâ¹°À̸ç, ¹éÇ÷º´, Á¾¾ç ¼¼Æ÷ÀÇ °íºÐÀÚ ÇÕ¼º, ¼¼Æ÷ÁÖ±â ÁøÇà, ¼¼Æ÷ »ç¸ê ¹× Áõ½ÄÀÇ °­·ÂÇÑ Á¶Àý ÀÎÀÚÀÌ´Ù. Avemar´Â Áõ½Ä¿¡ °ü·Ã ±¸Á¶ ¹× ±â´É °íºÐÀÚ (RNA, DNA) »çÀÌ¿¡ Æ÷µµ´ç ź¼Ò ºÐ¹è¿¡ °ü¿©ÇÏ´Â ´ë»ç È¿¼Ò¸¦ Á¶ÀýÇÑ´Ù. ¸²ÇÁ ¹éÇ÷º´ ¼¼Æ÷ÀÇ Áõ½ÄÀ» À§ÇØ ¾öû³­ °á°ú¸¦ °¡Á®¿Ã Áß¿äÇÑ ¼¼Æ÷ ³» ´ë»ç º¯È­ ¿¡ AvemarÀÇ Ä¡·á ¼ºÀû. '

J BIOL ÄÍ 277:46408¿¡¼­ 46414. 2002 ³â.
Ä«¹Î-Anduix B, º¼ ·Î½º L. G ¸¶¸° S, BOREN J, Callol-Ä­¸¶¼ÚÅä C, Centelles J. J Åä·¹½º J. L, Agell N, Bassilian S, Cascante M : ¹Ù¸£¼¿·Î³ª ´ëÇб³, ½ºÆäÀÎ
°úÇÐ ³í¹® - ¾Æ´Ï 30 Leukaemia3-pdf30.pdf


¿°Áõ¼º »çÀÌÅä Ä«ÀÎÀÇ »ý»ê ¹× RasÀÇ ¸Å°³ ¼¼Æ÷ È°¼ºÈ­¿¡ AvemarÀÇ ½Ã³ÊÁö È¿°ú.
'°ñ¼ö ¼¼Æ÷ (¿©±â¼­ P388D ¸¶¿ì½º °ñ¼ö¼º ¹éÇ÷º´ ¼¼Æ÷)°¡ ¸Å¿ì °­ÇÑ Áõ½Ä ¾ïÁ¦¸¦ º¸¿©ÁÖ°í AvemarÀÇ ¸éÀü¿¡¼­ »ýÁ¸À²À» °¨¼Ò½ÃÄ×´Ù'

¾Èµå¶ó ½´ Telekes, ¿£µµ·¹Å°½º-Toth ´Ô, Tünde ³ªµð :
¾û. N.Y.´Â ACAD. SCI. 1051:515¿¡¼­ 528. 2005 ³â.
°úÇÐ ³í¹® - ¾Æ´Ï 43 Leukaemia4-pdf43.pdf


¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹°ÀÌ Á¾¾ç T ¹× B ¼¼Æ÷ ¶óÀÎÀÇ ÁÖ¿ä Á¶Á÷ ÀûÇÕ¼º º¹ÇÕü Ŭ·¡½º I ´Ü¹éÁúÀÇ ¼¼Æ÷ »ç¸ê ¹× ´Ù¿î ·¹±Ö·¹À̼ÇÀ» À¯µµÇÑ´Ù.
ÀÇ Int J Oncol 20:563-570. 2002 ³â.
Fajka-Boja R, HidvégiM, Shoenfeld Y, ÀÌ¿Â G, Demydenko D, Tömösközi-FarkasÀÇ R, Vizler ¼¼½·, Telekes A, ResetárÁ, Monostori E :
°úÇÐ ³í¹® - ¾Æ´Ï 26 Leukaemia5-pdf26.pdf


Æó¾Ï
ü¿Ü [¿¬±¸½Ç]

½ÇÇè µ¿¹°ÀÇ Á¾¾ç ¼ºÀå°ú ÀüÀÌ¿¡ Avemar¿Í Avemar + ºñŸ¹Î CÀÇ È¿°ú.

'[Avemar] ¿ì¸®ÀÇ ±â´ë¿¡ »ì¾Ò´ø È®½ÇÈ÷ °­·ÂÇÑ »ý¹° È°¼ºÀ» º¸ÀÎÀÖ¾î ½É°¢ÇÑ Àå¾Ö ¸é¿ª ü°è¸¦ °¡Áø È£½ºÆ®ÀÇ ¸é¿ª ±â´ÉÀ» ÀÚ±ØÇÏ´Â °ÍÀÌ Áõ¸íµÇ°í ÀÖ½À´Ï´Ù. ±×°ÍÀº µ¶¼º ºÎÀÛ¿ëÀ» À¯¹ßÇÏÁö ¾Ê°í ¿©·¯ Á¾¾ç ¸ðµ¨¿¡¼­ °­·ÂÇÑ ÀüÀÌ ¾ïÁ¦ È¿°ú¸¦ º¸¿© ÁÖ¾ú´Ù. ÀÌ°ÍÀº Áغñ°¡ Àΰ£ÀÇ ¾Ï ¹ÙÀÌ¿À Ä¡·á Ä¡·á Àå¼Ò¸¦ ãÀ» °ÍÀ» ¹Ù¶ó°í ÀÖ½À´Ï´Ù. '

Ç×¾Ï ÇØ»óµµ 18:2353 ³â¿¡¼­ 2358 ³â. 1998.
HidvégiM, RASO E, Tömösközi-FarkasÀÇ R, ¹ÚÁö¼º S, ¶óÇǽº K, Szende B :
°úÇÐ ³í¹® - ¾Æ¹«µµ Æó Cancer1-pdf1.pdf


MSC, Avemar] Ç× ÀüÀÌ È¿°ú¸¦ °¡Áø »õ·Î¿î º¥Á¶ Äû³í ÇÔÀ¯ õ¿¬¹°.
'¿ì¸®ÀÇ in vitro ¹× in Avemar¸¦ ÀÌ¿ëÇÑ in vivo ½ÇÇè¿¡¼­ ÀϺΠµ¿¹° ½ÇÇè ¸ðµ¨¿¡¼­ °üÂû µÈÀÌ Á¦Ç°ÀÇ ¸Å¿ì Áß¿äÇÑ Ç× ÀüÀÌ È¿°ú¸¦ ÂüÁ¶ÇϽʽÿÀ. ´ëºÎºÐÀÇ °æ¿ìÀÌ È¿°ú´Â Ç× Áõ½Ä, ¼¼Æ÷ »ç¸ê, Á¢Âø °ü·ÃÇßÀ¸³ª ¹× ÀÚÀ¯ ¶óµðÄ®À» Çü¼ºÇÏ´Â È¿°ú´Â ¸ðµç ÀüÀÌ ¼Ò¼ö¿¡ ±â¿©ÇÒ ¼öÀÖ´Â in vivo ¹× in vitro ½ÃÇè ¸ðµÎ¿¡ ³ªÅ¸³ª´Â ¸é¿ª ÀÚ±Ø È¿°ú¿Í ¿¬°ü ÇÑ ³ª¸ÓÁö.

¾Ï Biother Radiopharm 14:277¿¡¼­ 289. 1999.
HidvégiM, RASO E, Tömösközi-FarkasÀÇ R, ¶óÇǽº K, Szende B :
°úÇÐ ³í¹® - ¾Æ´Ï 5 Æó Cancer2-pdf5.pdf


¸²ÇÁÁ¾
»ýü [µ¿¹° ½ÇÇè]

Avemar, ºñ µ¶¼º ¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹°Àº apoptosisÀÇ À¯µµ¸¦ ÅëÇØ ¹Î°¨ÇÏ°í 5-FdUrd/Ara-C ±³Â÷ ³»¼º H9 È÷Å丰ºü Áõ ¼¼Æ÷ÀÇ Áõ½ÄÀ» °¨¼è½ÃŲ´Ù.

'¿ì¸®ÀÇ °á°ú¿¡ ´ëÇؼ­´Â Avemar´Â H9 Àΰ£ÀÇ ¸²ÇÁÁ¾ ¼¼Æ÷¿¡ ±³Â÷ ³»¼º 5-FdUrd/Ara-CÀ» ±Øº¹ ÇÒ ¼ö ÀÖÀ¸¸ç, ¿ë·® ÀÇÁ¸¼ºÀÇ apoptosis¸¦ À¯µµÇÏ´Â °á·ÐÀ» ³»¸°´Ù. ¶ÇÇÑ ¹«µ¶¼º ¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹° ¸ðµÎ¿¡ ¹Î°¨¿Í ±³Â÷ ³»¼º H9 ¼¼Æ÷ÀÇ ÇöÀúÇÑ ¼¼Æ÷ÁÖ±âÀÇ È¥¶õÀ» ÃÊ·¡ÇÏÁö ¾Ê°í, ±×°ÍÀÌ ¼¼Æ÷ µ¶¼ºÀ» ¹ßÈÖÇÑ´Ù. '

787¿¡¼­ 791 : Á¾¾çÀº 21 ±Ç, Á¦ 3 È£¸¦º¸°íÇÕ´Ï´Ù. 2009 ³â.
¼­È£ P, Ozsvar-ÄÚÁ M, ±¸¶óÀÚ G, ¶ùÄí³ª A, Grusch M, Madlener S, Krupitza G, Àç±Ô¾î W, Hidvegi M, Agarwal ¾¾ RP, Fritzer-Á¬Ä«Áî M, Á¬Ä«Áî T
°úÇÐ ³í¹® - ¾Æ´Ï 59 Lymphoma1-pdf59.pdf

¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹°ÀÌ Á¾¾ç T ¹× B ¼¼Æ÷ ¶óÀÎÀÇ ÁÖ¿ä Á¶Á÷ ÀûÇÕ¼º º¹ÇÕü Ŭ·¡½º I ´Ü¹éÁúÀÇ ¼¼Æ÷ »ç¸ê ¹× ´Ù¿î ·¹±Ö·¹À̼ÇÀ» À¯µµÇÑ´Ù.
±¹Á¦ Àú³Î Á¾¾çÇÐ 20:563¿¡¼­ 570. 2002 ³â.
Fajka-Boja R, HidvégiM, Shoenfeld Y, ÀÌ¿Â G, Demydenko D, Tömösközi-FarkasÀÇ R, Vizler ¼¼½·, Telekes Àç¼³Á¤ RA, MonostoriÉ? :
°úÇÐ ³í¹® - ¾Æ´Ï 26 Lymphoma2-pdf26.pdf


Èæ»ö Á¾
Èæ»ö Á¾Àº ¸ðµç ¿¬·ÉÀÇ »ç¶÷µé¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â ¾ÏÀÇ ÀÏÁ¾ÀÔ´Ï´Ù. ÀÌ ÇǺξÏÀº ¾ÏÀÇ ÀϹÝÀûÀÎÇϸç ÀÎ½Ä °¡´ÉÇÑ Çü½ÄÀÔ´Ï´Ù. ¾Ç¼º Èæ»ö Á¾ÀÇ Á¾¾çÀº ÇǺξϰú °ü·ÃµÈ ¸ðµç »ç¸ÁÀÇ 75 %¸¦ ´ã´çÇÏ°í ÀÖ½À´Ï´Ù. ¾ÏÀÇ ´Ù¸¥ ÇüÅÂ¿Í ¸¶Âù°¡Áö·Î Èæ»ö Á¾ ¾Ï Ä¡·á´Â À§Çè°ú ¸ö¿¡ ÇØ·Î¿ï ¼ö ÀÖ°í, ¹æ»ç¼± ¿ä¹ý, È­ÇÐ ¿ä¹ý, ¼ö¼úÀÌ µÉ °¡´É¼ºÀÌ ÀÖ½À´Ï´Ù.

ºÒÇàÈ÷µµ, ¼¼°èÀÇ ¸¹Àº »ç¶÷µéÀº ÇǺΠÈæ»ö ÁõÀÇ ¿µÇâÀ» ¹Þ¾Æ Èæ»ö Á¾ ¾Ï Ä¡·áÀÇ ¿©·¯ ÇüŸ¦ ÇÊ¿ä·ÎÇÕ´Ï´Ù. Èæ»ö Á¾ ¾Ï Ä¡·áÀÇ ¿¬±¸´Â ȯÀÚ°¡ º¸¿Ï ¾Ï Ä¡·á·Î¼­ ȤÀº ÁÖ·ù Ä¡·á¹ýÀÇ ´ë¾ÈÀ¸·Î Avemar¸¦ »ç¿ëÇÏ¿© ¹«¼­¿î Áúº´¿¡¼­ ±¸Á¦¸¦ ¾òÀ» ¼öÀÖ´Â °ÍÀ» ÀǹÌÇÏ°íÀÖ´Ù.

Avemar È®ÀÎ °úÇÐÀûÀÎ Å×½ºÆ®¸¦ ÅëÇØ Æ¯Á¤ ¿¬±¸´Â ´ëü ¾Ï Ä¡·á·Î¼­ ȤÀº º¸¿Ï ¾Ï Ä¡·á·Î »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ´ëü ¶Ç´Â º¸¿ÏÀûÀÎ ¾Ï Ä¡·á·Î ¹Ýµå½Ã Avemar »ç¿ëÀÌ È¿°úÀûÀÎ Èæ»ö Á¾ ¾ÏÀÇ Ä¡·á´Â ÇöÀç »ç¿ëÇÒ ¼ö ÀÖ´ÂÁö È®ÀÎÇÕ´Ï´Ù.

Àΰ£ ÇкÎ

7 ³â°£ÀÇ ÃßÀû¿¡¼­ ¹«ÀÛÀ§, ÆÄÀÏ·µ, Á¦ II »ó ÀÓ»ó ½ÃÇè : µµ¿òÀ̵Ǵ ¹ßÈ¿ ¹Ð ¹è¾Æ ÃßÃâ¹° (Avemar) ¿µ¾ç º¸Á¶ ½ÄÇ°Àº ³ôÀº À§Çè ÇǺΠÈæ»ö Á¾ ȯÀÚÀÇ »ýÁ¸À» °³¼±ÇÑ´Ù.

'¿ì¸®´Â µû¶ó¼­ ¸Å¿ì À§ÇèÀÌ ³ôÀº ÇǺΠÈæ»ö Á¾ ȯÀÚ¿¡ µµ¿òÀ̵Ǵ ÇÁ·ÎÅäÄÝÀÌ ¹ßÈ¿ µÈ ¹Ð ¹è¾Æ ÃßÃâ¹° ±â¹ÝÀÇ ÀÇ·á ¿µ¾çÀ» Æ÷ÇÔÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù. ¿ì¸®´Â ¶ÇÇÑ Èæ»ö Á¾°ú Àΰ£ ¾ÏÀÇ ´Ù¸¥ À¯ÇüÀÌ µ¶¼º È°¼º Áغñ¸¦ Å×½ºÆ®Çϱâ À§ÇØ ÆÀ µ¿·á¸¦ Àå·ÁÇÏ°í ÀÖ½À´Ï´Ù. '

¾Ï Biother Radiopharm º¼·ý 23, Á¦ 4 È£ : 477¿¡¼­ 482. 2008
µ¥¹Ì µµÇÁ L. V, Manziuk L. V, Kharkevitch G. Y; Pirogova, N. A; Artamonova, E. V :
°úÇÐ ³í¹® - ¾Æ´Ï 55 Melanoma1-pdf55.pdf


À§Çèµµ°¡ ³ôÀº Èæ»ö Á¾ ȯÀÚÀÇ Avemar Ç× ÀüÀÌ È¿°ú. 18 UICC ±¹Á¦ ¾Ï ÀÇȸ.
'ÀÌ ¿¹ºñ µ¥ÀÌÅÍ´Â ·çƾ DTIC È­ÇÐ ¿ä¹ý°ú AVEMAR ±× Á¶ÇÕÀ» Ç¥½Ã ÇϽðڽÀ´Ï±î? Àç¹ß À§ÇèÀ» °¨¼Ò½ÃÄÑ Èæ»ö ÁõÀÇ ÁøÇà ½Ã°£À» ¿¬±â ÇÒ ¼öÀÖ´Ù. °ø°³ ÀüÀÓ»ó °á°ú´Â AVEMAR Ç× ÀüÀÌ È¿°ú? ±× ¼¼Æ÷ Á¢Âø ÀúÇØ, ¼¼Æ÷ Áõ½Ä ¾ïÁ¦, ¼¼Æ÷ »ç¸ê Áõ°¡ÇÏ°í Ç×»êÈ­ Ư¼º°ú °ü·Ã. '

¿À½½·Î, ³ë¸£¿þÀÌ. 30. 6 ¿ù - 5. 2002 ³â 7 ¿ù. (¿ä¾à)ÀÇ Int J ¾Ï 100 (S13) : 408. 2002 ³â. µ¥¹Ì µµÇÁ L. V, Manzjuk L. V, Kharkevitch G. Y, Artamonova E. V, Pirogova N. : °úÇÐ ³í¹® - ¾Æ´Ï 28 Melanoma2-pdf28.pdf


ü¿Ü [¿¬±¸½Ç]
½ÇÇè µ¿¹°ÀÇ Á¾¾ç ¼ºÀå°ú ÀüÀÌ¿¡ Avemar¿Í Avemar + ºñŸ¹Î CÀÇ È¿°ú.

'[Avemar] ¿ì¸®ÀÇ ±â´ë¿¡ »ì¾Ò´ø È®½ÇÈ÷ °­·ÂÇÑ »ý¹° È°¼ºÀ» º¸ÀÎÀÖ¾î ½É°¢ÇÑ Àå¾Ö ¸é¿ª ü°è¸¦ °¡Áø È£½ºÆ®ÀÇ ¸é¿ª ±â´ÉÀ» ÀÚ±ØÇÏ´Â °ÍÀÌ Áõ¸íµÇ°í ÀÖ½À´Ï´Ù. ±×°ÍÀº µ¶¼º ºÎÀÛ¿ëÀ» À¯¹ßÇÏÁö ¾Ê°í ¿©·¯ Á¾¾ç ¸ðµ¨¿¡¼­ °­·ÂÇÑ ÀüÀÌ ¾ïÁ¦ È¿°ú¸¦ º¸¿© ÁÖ¾ú´Ù. ÀÌ°ÍÀº Áغñ°¡ Àΰ£ÀÇ ¾Ï biotherapeutical Ä¡·á Àå¼Ò¸¦ ãÀ» °ÍÀ» ¹Ù¶ó°í ÀÖ½À´Ï´Ù. '

Ç×¾Ï ÇØ»óµµ 18:2353 ³â¿¡¼­ 2358 ³â. 1998.
HidvégiM, RASO E, Tömösközi-FarkasÀÇ R, ¹ÚÁö¼º S, ¶óÇǽº K, Szende B :
°úÇÐ ³í¹® - ¾Æ´Ï 1 Melanoma3-pdf1.pdf

MSC, Avemar] Ç× ÀüÀÌ È¿°ú¸¦ °¡Áø »õ·Î¿î º¥Á¶ Äû³í ÇÔÀ¯ õ¿¬¹°.
'¿ì¸®ÀÇ in vitro ¹× in Avemar¸¦ ÀÌ¿ëÇÑ in vivo ½ÇÇè¿¡¼­ ÀϺΠµ¿¹° ½ÇÇè ¸ðµ¨¿¡¼­ °üÂû µÈÀÌ Á¦Ç°ÀÇ ¸Å¿ì Áß¿äÇÑ Ç× ÀüÀÌ È¿°ú¸¦ ÂüÁ¶ÇϽʽÿÀ. ´ëºÎºÐÀÇ °æ¿ìÀÌ È¿°ú´Â Ç× Áõ½Ä, ¼¼Æ÷ »ç¸ê, Á¢Âø °ü·ÃÇßÀ¸³ª ¹× ÀÚÀ¯ ¶óµðÄ®À» Çü¼ºÇÏ´Â È¿°ú´Â ¸ðµç ÀüÀÌ ¼Ò¼ö¿¡ ±â¿©ÇÒ ¼öÀÖ´Â in vivo ¹× in vitro ½ÃÇè ¸ðµÎ¿¡ ³ªÅ¸³ª´Â ¸é¿ª ÀÚ±Ø È¿°ú¿Í ¿¬°ü ³Ê¹«. '

¾Ï Biother Radiopharm 14:277¿¡¼­ 289. 1999.
HidvégiM, RASO E, Tömösközi-FarkasÀÇ R, ¶óÇǽº K, Szende B :
°úÇÐ ³í¹® - ¾Æ´Ï 5 Melanoma4-pdf5.pdf


ÃéÀå¾Ï
ü¿Ü [¿¬±¸½Ç]
¹Ð ¹è¾Æ ÃßÃâ¹°Àº Æ÷µµ´ç ÀÌÇØ ¹× RNA ¸®º¸¿À½ºÀÇ Çü¼ºÀ» °¨¼Ò ½ÃÄ×Áö¸¸ MIA ÃéÀå ¼±¾Ï ¼¼Æ÷¿¡¼­ Áö¹æ»ê ÇÕ¼ºÀ» Áõ°¡½ÃŲ´Ù.

̎ˌ 23:141-147. 2001.
º¼ ·Î½º L. G, ¶óÇǽº K, Szende B, Tömösközi-FarkasÀÇ R, ¹Ù·Î±¸ Á, BOREN J, ¸¶¸° S, Cascante M, HidvégiM :
°úÇÐ ³í¹® - ¾Æ´Ï 10 ÃéÀå Cancer1-pdf10.pdf

ÃéÀå¾ÏÀÇ ¼¼Æ÷ Áõ½Ä°ú Á×À½ÀÇ ´ë»ç °¡¼³.
'°á·Ð : Áõ°Å´Â TGF-B ¼¼Æ÷ ÇüÁú Àüȯ Á¦¿Í ±×·± Á¦´Ï½ºÅ×ÀÎ ¹× Avemar ¶Ç´Â STI571 (±Û¸®º¤) µîÀÇ »õ·Î¿î ÇÕ¼º Ç× ¹éÇ÷º´ ¾àÀ¸·Î Á¾¾çÀÇ Áõ½Ä ¾ïÁ¦ ½Ä¹° È­ÇÐ ¹°Áú¿¡ ÀÇÇØ À¯µµ µÈ ´ë»ç Ç¥Çö Çü½Ä¿¡ ¹Ý´ë º¯È­¸¦ º¸¿© ±× Á¦½Ã. ¼ºÀå ½ÅÈ£ Àü´Þ °æ·Î¸¦ ¸Å°³ ¾Ç¼º ¼¼Æ÷ ÇüÁú ÀüȯÀ» ÃËÁøÇÏ´Â Áß°£ ´ë»ç È¿¼Ò´Â ¾Ï Ä¡·á¸¦À§ÇÑ °íÈ¿À² ºñ À¯Àü ½Å±Ô Ç¥ÀûÀ¸·Î¼­ÀÇ ¿ªÇÒÀ» ÇÒ ¼öÀÖ´Ù. "

 

¼¼°èÀûÀÎ ¾Æº£¸¶¸£ »ý»ê°øÁ¤

 

 

 

 

´ë¸¸ ¾Æº£¸¶¸£ ¼Ò°³ ¿µ»ó



 
¢¹ ÀϺ»¿¡¼­ ¹ß¼ÛÇÏ´Â Á¦Ç°Àº ÁÖ¸»À» Á¦¿ÜÇÏ°í 3-7ÀÏ ¼Ò¿äµË´Ï´Ù.
     ±¹Á¦Æ¯±Þ¿ìÆí(EMS) À¸·Î ¹ß¼Û µÇ¸ç ¾Æ·¡ »çÀÌÆ®¿¡¼­ ¹è¼Û È®ÀÎÀÌ °¡´ÉÇÕ´Ï´Ù.
¢¹ ´ºÁú·£µå/È£ÁÖ ¹ß¼Û Á¦Ç°Àº ÁÖ¹®½Ã ÁÖ¸»À» Á¦¿ÜÇÑ 5-7ÀÏ ³»¿Ü°¡ ¼Ò¿äµË´Ï´Ù.
¢¹ ¹Ì±¹ ¹ß¼ÛÁ¦Ç°Àº ±¹Á¦ Ư¼Û¾÷ü¸¦ ÅëÇØ ¹ß¼ÛµÇ¸ç ÁÖ¹®½Ã ÁÖ¸»À» Á¦¿ÜÇÏ°í 10ÀÏ ³»¿Ü°¡ ¼Ò¿äµË´Ï´Ù.

Health 2580 Á¦Ç°Àº ±¸¸Å ±Ý¾× ¹× ¹ß¼Û ±¹°¡¿¡ µû¶ó °¢±â ¹è¼Ûºñ Àû¿ëÀÌ ´Ù¸¨´Ï´Ù.
ÁÖ¹®½Ã ¹è¼Ûºñ À¯¹«¸¦ Àß È®ÀÎ ÈÄ ÁÖ¹®ÇØ Áֽñ⠹ٶø´Ï´Ù.

    - ´ºÁú·£µå Á¦Ç°: 7¸¸¿ø ÀÌÇÏ ±¸¸Å½Ã ÀÏ°ýÀûÀ¸·Î 5õ¿øÀÇ ¹è¼Ûºñ¸¦ ºÎ´ã
    - ¹Ì±¹ ¹ß¼Û Á¦Ç°: Á¦Ç°¸¶´Ù ¹«·á ¹è¼Û ±âÁØÀÌ ´Ù¸¨´Ï´Ù. È®ÀÎ ÈÄ ÁÖ¹®Çϼ¼¿ä.
    - ÀϺ» ¹ß¼Û Á¦Ç°: ¿øÄ¢ÀûÀ¸·Î ¹è¼Ûºñ°¡ Æ÷ÇԵǾî ÀÖ½À´Ï´Ù. ¹è¼Ûºñ ¹ß»ý Á¦Ç°Àº º°µµ Ç¥±âÇÕ´Ï´Ù.
    - Çѱ¹ ¹ß¼Û Á¦Ç°: 3¸¸¿ø ÀÌ»ó ±¸¸Å ½Ã ¹«·á ¹è¼ÛÀÔ´Ï´Ù.

¢¹ Health2580 ÀüÁ¦Ç°Àº ÃÖ°íÀÇ Á¦Ç°¸¸À» ¾ö¼±ÇÕ´Ï´Ù.
¢¹ ÀϺΠ±¹³» ¹è¼ÛÁ¦Ç°À» Á¦¿ÜÇÑ Health2580ÀÇ ¸ðµç Á¦Ç°Àº ÇØ¿Ü¿¡¼­ Á÷Á¢ ¼ÒºñÀÚ¿¡°Ô ¹ß¼ÛµË´Ï´Ù.
     Åë°ü½Ã °ü¼¼°¡ ¹ß»ýµÇÁö ¾Êµµ·Ï ¸¸¹ÝÀÇ Áغñ¸¦ ÇÏ°í ÀÖ½À´Ï´Ù. ¸¸ÀÏ °ü¼¼°¡ ¹ß»ýÇÒ °æ¿ì Health2580¿¡¼­
     ¸ðµç ºñ¿ëÀ» ³³ºÎÇØ µå¸³´Ï´Ù.
¢¹ ÇØ¿Ü ¹ß¼Û ÁÖ¹®ÀÇ °æ¿ì °ü¼¼Ã»¿¡¼­ ¹ß±ÞÇÏ´Â °³ÀÎÅë°üºÎÈ£°¡ ÇÊ¿äÇÕ´Ï´Ù. ÁÖ¹®ÇϽŠ»óÇ°ÀÌ °³ÀÎÅë°üºÎÈ£°¡ ÇÊ¿äÇÑ »óÇ°ÀÏ °æ¿ì º°µµ·Î À¯¼±À¸·Î °³ÀÎÅë°üºÎÈ£ ¹ß±Þ ¹æ¹ýÀ» ¾È³»ÇØ µå¸³´Ï´Ù. ÀúÈñ »ç¹«¼Ò¿¡¼­ Àç°í È®º¸°¡ µÇ¾î ÀÖ´Â »óÇ°Àº Åë°üºÎÈ£ ¾øÀÌ ¼­¿ï»ç¹«¼Ò¿¡¼­ ¹ß¼ÛµË´Ï´Ù..
¢¹ ÇØ¿Ü ¹è¼Û »óÇ°Àº Ư¼º»ó ÁÖ¹®½Ã Ãë¼Ò°¡ ºÒ°¡´É ÇÕ´Ï´Ù. Á¦Ç° ÇÏÀÚ·Î ÀÎÇÑ ±³È¯,ȯºÒÀº ¾ðÁ¦µç °¡´ÉÇÕ´Ï´Ù¸¸,
     ¼ÒºñÀÚ ´Ü¼ø º¯½ÉÀ¸·Î ÀÎÇÑ ÁÖ¹® Ãë¼Ò´Â ºÒ°¡´ÉÇÑ Á¡ ¾çÇØ ¹Ù¶ø´Ï´Ù.

 
 
   
 
Copyright ¨Ï Çコ2580 All Rights Reserved.
»óÈ£¸í : Çコ2580 »ç¾÷ÀÚµî·Ï¹øÈ£ : NZ1143681 ´ëÇ¥ : Samuel Kim
[ÀÌ¿ë¾à°ü] °³ÀÎÁ¤º¸ º¸È£Á¤Ã¥ °³ÀÎÁ¤º¸´ã´çÀÚ : Dennis Han
»ç¾÷Àå¼ÒÀçÁö ÀϺ» : 115-18, NOGATA 1-CHOME, NAKANO-KU, TOKYO
[TEL] 03-3387-2371 / [FAX] 03-3387-2300
´ºÁú·£µå : Curraghs RD RD6 Christchurch New Zealand